CSCC
Keytruda Gains Indication for Locally Advanced Squamous Cell Carcinoma
The FDA approved an additional indication for pembrolizumab (Keytruda, Merck)—monotherapy for locally ...
JULY 13, 2021

FDA Approves Libtayo as First and Only Treatment for Advanced CSCC
Libtayo is a fully human monoclonal antibody that targets the immune checkpoint receptor PD-1 and works by blocking ...
SEPTEMBER 28, 2018

Load more